BridgeBio Pharma Inc (FRA:2CL)
€ 24.95 -0.37 (-1.46%) Market Cap: 4.78 Bil Enterprise Value: 5.91 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 45/100

BridgeBio Pharma Inc to Discuss Additional Data from the Phase 3 ATTRibute-CM Study Transcript

Nov 12, 2023 / 04:15PM GMT
Operator

Good day and thank you for standing by. Welcome to today's discussion with BridgeBio, which will cover the company's additional clinical outcomes data from the Phase 3 ATTRibute-CM study in patients with transthyretin amyloid cardiomyopathy. (Operator Instructions) Please be advised that today's conference is being recorded.

I would now like to introduce your speaker today, Dr. Daniel Judge, Professor of Medicine and Cardiology at Medical University of South Carolina and Co-Chair of the ATTRibute-CM Steering Committee; Dr. Neil Kumar, Chief Executive Officer, BridgeBio Pharma; Dr. Jonathan Fox, Chief Medical Officer, BridgeBio Pharma, Cardio and Renal.

I would now like to hand it over to Dr. Kumar.

Neil Kumar
BridgeBio Pharma, Inc. - Co-Founder, President, CEO & Director

Thanks so much, operator, and thanks to everyone who's listening in. Happy Diwali. I'll make my introductory remarks brief as I'm excited to listen to and learn from Dr. Judge today. I'll start briefly where I always start, which is a hearty thank you to the patients,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot